Optison (perflutren)
- Region
- 🇪🇺 EU
- Active substance
- perflutren
- Company
- GE Healthcare AS
- Status
- Authorised
- Therapeutic area
- Echocardiography
- EU approval
- Sun 17 May 1998
- Application
- EMEA/H/C/000166
- ATC
- V08DA01
- Official record
- www.ema.europa.eu
Indication
This medicinal product is for diagnostic use only. Optison is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left-ventricular-endocardial-border delineation with resulting improvement in wall-motion visualisation. Optison should only be used in patients where the study without contrast enhancement is inconclusive.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Luminity Authorised · Lantheus EU Limited
Follow Optison
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.